You searched for "practice"
Case series of toxic anterior segment syndrome
Herein we report two cases of toxic anterior segment syndrome (TASS) following uneventful cataract surgery. Both patients presented 24 hours after their uneventful operations with painless blurred vision in the operated eye. The inflammatory reaction was controlled successfully with an...An update on inherited retinal disorders (part 1) – overview and assessment of inherited retinal disease
1 October 2016
| Michel Michaelides (Prof)
|
EYE - Vitreo-Retinal
Part 2 of this topic can be found here Inherited Retinal Disease (IRD) is the leading cause of blindness certification in the working age population (age 16-64 years) in England and Wales and the second most common in childhood [1]....
Management of diabetic macular oedema in vitrectomised eyes
1 August 2016
| Maged Habib
|
EYE - Vitreo-Retinal
Diabetic macular oedema (DMO) is one of the leading causes of blindness; its prevalence is on the rise with progressive increase in numbers of people suffering from diabetes. The management of DMO has evolved significantly over the past few years....
Newer generation IOL platforms designed for high-quality visual performance after cataract surgery
Expanding intraocular lens (IOL) capabilities provide broadening options, ranging from next-generation monofocal IOLs for basic cataract surgery, to specialised premium IOLs for lens-based presbyopia correction and astigmatism correction at the time of cataract surgery. Rod McNeil considers several newer alternative...Ambitions for sustainable service recovery amidst an escalating post-COVID backlog
5 April 2022
| Rod McNeil, Andrew Tatham
|
EYE - General
Rod McNeil reviews plans, activity and solutions to better address the post-COVID backlog and bolster sustainable service recovery. Ophthalmology was the busiest outpatient specialty during the three years to March 2020 across the English NHS and again recorded the highest...
Broadening of treatment options for potentially blinding retinal conditions
2 August 2022
| Rod McNeil
|
EYE - General
Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...
East Bound and Down: Patrick Staropoli
2 August 2024
| Peter Cackett
|
EYE - General
One of my heroes growing up in the 70s was the iconic Formula 1 racing driver, James Hunt. At the time, if you had asked me and my primary school friends what we would most like to do for a...
East Bound and Down: Patrick Staropoli
2 August 2024
| Peter Cackett
|
EYE - General
One of my heroes growing up in the 70s was the iconic Formula 1 racing driver, James Hunt. At the time, if you had asked me and my primary school friends what we would most like to do for a...
Update on emerging therapies for age-related macular degeneration
4 December 2023
| Rod McNeil
|
EYE - Vitreo-Retinal
The 23rd European Society of Retina Specialists (EURETINA) Congress, held in Amsterdam, the Netherlands, provided a timely update on anti-complement therapy for geographic atrophy and emerging investigational therapies for neovascular age-related macular degeneration. Anti-complement therapy for geographic atrophy Geographic atrophy...
The curse of the college museum
4 December 2024
| Peter Cackett
|
EYE - General
David Greig lecture notebook. Courtesy of Dr Jacqueline Cahif, College Archivist, Royal College of Surgeons of Edinburgh. As sure as the inevitability of death and taxes, the hidden stories of past events will intermittently rise to the surface like oil...